Pneumocell研究:对IgG1和IgG2缺陷患者接种Prevnar13疫苗
该小型先导研究纳入IgG1和/或IgG2缺陷患者10例及年龄性别匹配健康对照10例,接种Prevnar13后1、2、4周检测调理吞噬活性滴度和抗肺炎球菌IgG抗体。患者多数血清型调理吞噬活性滴度低于对照,但对6A和6B血清型疫苗应答接近正常,5/10患者对至少一种血清型产生疫苗应答,多数患者4周时达到推测保护水平。
要点
- IgG缺陷患者多数血清型调理吞噬活性滴度低于健康对照。
- 5/10患者对至少一种血清型产生疫苗应答。
- 多数患者4周时达到调理吞噬活性滴度≥8和抗肺炎球菌IgG≥0.35µg/ml。
核心结论
- 对IgG缺陷患者接种Prevnar13可能具有临床获益,初步发现将为该脆弱人群的未来疫苗试验提供框架。
研究设计与样本
- 小型先导研究纳入IgG1和/或IgG2缺陷患者10例及年龄性别匹配健康对照10例。
- 接种前及接种后1、2、4周采集血清、血浆和肝素血,分析调理吞噬活性滴度和抗肺炎球菌IgG抗体水平。
主要发现
- 患者多数血清型调理吞噬活性滴度普遍低于对照,但对6A和6B血清型疫苗应答接近正常。
- 5/10患者对至少一种血清型产生疫苗应答。
- 多数患者接种后4周时对多数血清型达到推测保护水平的调理吞噬活性滴度≥8和抗肺炎球菌IgG水平0.35µg/ml。
关键数值与推荐
- 推测保护水平为调理吞噬活性滴度≥8和抗肺炎球菌IgG水平0.35µg/ml。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with IgG-deficiency often suffer from repeated bacterial infections with S. pneumoniae. Since there is a lack of knowledge regarding whether IgG-deficient patients would benefit from conjugate pneumococcal vaccination, we set out to evaluate the effect of Prevnar13 vaccination in IgG1- and/or IgG2-deficient patients. METHOD: We designed a small pilot-study including IgG1- and/or IgG2-deficient patients (n=10) and age- and sex-matched healthy controls (n=10). Serum, plasma and heparin-blood were collected prior to vaccination, as well as 1, 2 and 4weeks post vaccination, and the levels of opsonophagocytic activity (Opa) titers and anti-pneumococcal IgG-antibodies were analyzed. RESULTS: Patients generally had lower Opa-titers than controls for most serotypes, but they exhibited an almost normal vaccine response to serotypes 6A and 6B. Notably, 5/10 patients showed vaccine-response to at least one serotype. Most patients reached the presumably protective levels of Opa-titers ≥8 and anti-pneumococcal IgG levels of 0.35µg/ml by 4weeks post-vaccination for a majority of the serotypes. CONCLUSION: Our results show that vaccination of IgG-deficient patients with Prevnar13 is likely to have a clinical benefit. Our initial findings will provide a framework for future vaccine-trials in this vulnerable patient group. Registered at www.clinicaltrials.gov as NCT01847781.
引用
- Zangenah S, Björkhem-Bergman L, Norlin AC, et al. The Pneumocell-study: Vaccination of IgG1- and IgG2-deficient patients with Prevnar13. Vaccine. 2017. PMID: 28410816. doi:10.1016/j.vaccine.2017.03.097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。